2018 年第 12 期 第 13 卷

培美曲塞联合PC化疗方案治疗晚期肺腺癌的效果及对血清癌胚抗原和半乳糖凝集素1水平的影响

Effect of pemetrexed combined with PC chemotherapy on advanced lung adenocarcinoma, serum carcinoembryonic antigen and galectin-1

作者：顾玉琴华燕艳李杰

英文作者：

单位：225009江苏省扬州友好医院内科（顾玉琴）；214062江苏省无锡市，江南大学附属医院肿瘤科（华燕艳、李杰）

英文单位：

关键词：肺腺癌；PC化疗方案；培美曲塞；癌胚抗原；半乳糖凝集素1

英文关键词：

• 摘要：

• 【摘要】目的    探讨培美曲塞联合PC化疗方案治疗晚期肺腺癌的效果及对血清癌胚抗原和半乳糖凝集素1(Gal-1)水平的影响。方法    选取2015年1月至2017年12月扬州友好医院收治的100例晚期肺腺癌患者，依据随机数字表法分为观察组和对照组，每组50例。对照组使用PC化疗方案进行治疗，观察组使用培美曲塞联合PC化疗方案治疗，2组均以21 d为1个周期，治疗4个周期。观察2组患者肿瘤控制率，血清癌胚抗原、Gal-1水平，T细胞亚群水平以及不良反应发生情况。结果    治疗后，观察组肿瘤控制率高于对照组［48.0%(24/50)比32.0%(16/50)］（P=0.04）。治疗后，2组血清癌胚抗原、Gal-1水平均明显低于治疗前，且观察组明显低于对照组，2组CD+3、CD+4、CD+8水平和CD+4/CD+8比值均明显高于治疗前，且观察组均明显高于对照组，差异均有统计学意义（均P＜0.05）。2组治疗期间恶心呕吐、静脉炎、肝功能异常发生率比较差异均无统计学意义（均P＞0.05）。结论    培美曲塞联合PC化疗方案治疗晚期肺腺癌，能降低血清癌胚抗原、Gal-1水平，提高患者免疫能力，增加患者的肿瘤控制率，且安全性较好。

• 【Abstract】Objective    To explore the effect of pemetrexed combined with PC chemotherapy on advanced lung adenocarcinoma, serum carcinoembryonic antigen（CEA） and galectin-1(Gal-1). Methods    From January 2015 to December 2017, 100 patients with advanced lung adenocarcinoma in Friendliness Hospital Yangzhou were randomly divided into observation group and control group, with 50 cases in each group. The control group was treated with PC chemotherapy; the observation group was treated with PC chemotherapy combined with pemetrexed; one course was 21 d; both groups were treated for 4 courses. Tumor control rate, CEA, Gal-1, T cell subsets and adverse reactions were analyzed. Results    After treatment, tumor control rate in the observation group was significantly higher than that in the control group［48.0%(24/50) vs 32.0%(16/50)］（P=0.04）. Levels of serum CEA and Gal-1 decreased after treatment in both groups; the levels in the observation group were significantly lower than those in the control group(P＜0.05). CD+3, CD+4, CD+8 and CD+4/CD+8 increased after treatment; the levels in the observation group were significantly higher than those in the control group(P＜0.05). There was no significant difference of adverse reactions between groups(P＞0.05). Conclusion    PC chemotherapy combined with pemetrexed treating advanced lung adenocarcinoma can effectively reduce serum CEA and Gal-1, enhance immunocompetence and increase the tumor control rate with a good safety.